Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Accounts Payables (2016 - 2025)

Integra Lifesciences Holdings (IART) has disclosed Accounts Payables for 17 consecutive years, with $95.7 million as the latest value for Q4 2025.

  • Quarterly Accounts Payables rose 16.03% to $95.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $95.7 million through Dec 2025, up 16.03% year-over-year, with the annual reading at $95.7 million for FY2025, 16.03% up from the prior year.
  • Accounts Payables hit $95.7 million in Q4 2025 for Integra Lifesciences Holdings, up from $92.3 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $112.8 million in Q1 2023 to a low of $59.6 million in Q3 2021.
  • Historically, Accounts Payables has averaged $86.1 million across 5 years, with a median of $91.8 million in 2025.
  • Biggest five-year swings in Accounts Payables: crashed 36.64% in 2021 and later soared 65.11% in 2022.
  • Year by year, Accounts Payables stood at $61.8 million in 2021, then skyrocketed by 65.11% to $102.1 million in 2022, then decreased by 9.57% to $92.3 million in 2023, then fell by 10.64% to $82.5 million in 2024, then grew by 16.03% to $95.7 million in 2025.
  • Business Quant data shows Accounts Payables for IART at $95.7 million in Q4 2025, $92.3 million in Q3 2025, and $92.8 million in Q2 2025.